In a recent video update to stockholders, Vaxart’s Founder and Chief Scientific Officer discussed the latest advancements in recombinant vaccine platforms. The update highlighted the company’s plans, objectives, and expectations for business operations, funding, financial performance, and regaining compliance with Nasdaq requirements. While emphasizing forward-looking statements, the update also addressed the potential risks and uncertainties involved in the industry. Stockholders were urged to carefully consider the factors and risks outlined in the company’s reports filed with the SEC. As Vaxart continues to innovate in the field of vaccine development, the video update provided insight into the future direction of the company’s research and development efforts.
Read more about this — here
